Compare Ascendis Pharma A/S (ASND) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs DENTSPLY SIRONA Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while DENTSPLY SIRONA Inc trades at $12.26 (market cap $2.46B). The key difference: Ascendis Pharma A/S is far larger — about 7.2× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | XRAY | |
|---|---|---|
Market Cap | $17.74B | $2.46B |
Sector | Health | Health |
52-Week High | $277.18 | $16.85 |
52-Week Low | $163.32 | $9.64 |
Enterprise Value | $18.11B | $4.60B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Dentsply Sirona (XRAY) trades at $12.26, up 3.11% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $598M in 2025, with negative profit margins and declining revenue trends. Recent news highlights distribution expansion and new AI product launches, while earnings have missed estimates for three consecutive quarters.
The outlook remains challenging with persistent losses and high debt levels, though analyst consensus suggests moderate upside to the $12.50 price target. Key risks include margin pressure and soft European demand, while potential catalysts include digital dentistry adoption and cost management under new CFO leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
